
    
      This is a dose-finding / dose escalation phase I trial of ABT-888 (Veliparib) in combination
      with Bortezomib and Dexamethasone in patients with relapsed or refractory multiple myeloma.
      ABT-888 is given orally (PO) twice daily (every 12 hours) for 14 days in a 21 days cycle.

      First dose to be given within 1 hour of Bortezomib on day 1. Planned starting dose is 20 mg
      PO every 12 hours. Starting dose escalation is planned until an MTD is reached.
    
  